$4.91
3.35% day before yesterday
Nasdaq, Dec 27, 09:49 pm CET
ISIN
US1856341029
Symbol
CLNN
Sector
Industry

Clene Inc Stock price

$4.99
+0.84 20.24% 1M
-2.39 32.38% 6M
-0.94 15.88% YTD
-0.21 4.04% 1Y
-75.01 93.76% 3Y
-204.21 97.61% 5Y
-188.01 97.41% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.09 1.77%
ISIN
US1856341029
Symbol
CLNN
Sector
Industry

Key metrics

Market capitalization $39.82m
Enterprise Value $48.05m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 114.40
P/S ratio (TTM) P/S ratio 94.81
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -41.36%
Revenue (TTM) Revenue $420.00k
EBIT (operating result TTM) EBIT $-34.37m
Free Cash Flow (TTM) Free Cash Flow $-23.76m
Cash position $14.65m
EPS (TTM) EPS $-0.28
P/E forward negative
P/S forward 123.83
EV/Sales forward 149.42
Short interest 2.24%
Show more

Is Clene Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Clene Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Clene Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Clene Inc forecast:

Buy
100%

Financial data from Clene Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.42 0.42
42% 42%
100%
- Direct Costs 1.75 1.75
17% 17%
417%
-1.33 -1.33
4% 4%
-317%
- Selling and Administrative Expenses 12 12
7% 7%
2,764%
- Research and Development Expense 20 20
25% 25%
4,707%
-33 -33
19% 19%
-7,788%
- Depreciation and Amortization 1.66 1.66
17% 17%
395%
EBIT (Operating Income) EBIT -34 -34
19% 19%
-8,183%
Net Profit -36 -36
11% 11%
-8,576%

In millions USD.

Don't miss a Thing! We will send you all news about Clene Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Clene Inc Stock News

Neutral
GlobeNewsWire
19 days ago
SALT LAKE CITY, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it recent...
Neutral
GlobeNewsWire
3 months ago
SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS),...
Neutral
GlobeNewsWire
3 months ago
SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclero...
More Clene Inc News

Company Profile

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Robert Etherington
Employees 85
Founded 2013
Website www.clene.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today